Product How it works Pricing Blog FAQ About Contact
Recursion Pharmaceuticals

Recursion Pharmaceuticals (NASDAQ: RXRX) revenue

Recursion Pharmaceuticals reported revenue of $74.7m for fiscal 2025, 26.9% more than in fiscal 2024 ($58.8m). Since fiscal 2020 its revenue has grown by 1,784.9%, an average growth of 79.9% a year.

Recursion Pharmaceuticals has grown its revenue for 5 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record.

Revenue, in millions of US dollars4.0202010.2202139.8202244.6202358.8202474.72025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$74.7m+26.9%−$648.1m−867.9%
2024$58.8m+32.0%−$479.0m−814.1%
2023$44.6m+11.9%−$350.1m−785.3%
2022$39.8m+291.5%−$245.7m−616.7%
2021$10.2m+156.9%−$182.8m−1,795.8%
2020$4.0m—−$84.6m−2,135.7%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Recursion Pharmaceuticals revenue compared with its sector

By revenue for its latest fiscal year, Recursion Pharmaceuticals ranks 308th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Recursion Pharmaceuticals, 26.9%.

RankCompanyRevenueRevenue growth
306thCytomX Therapeutics$76.2m−44.8%
307thAbCellera Biologics$75.1m160.6%
308thRecursion Pharmaceuticals$74.7m26.9%
309thElectromed$73.8m15.3%
310thAssembly Biosciences$72.3m153.5%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Recursion Pharmaceuticals

How much revenue did Recursion Pharmaceuticals make in fiscal 2025?
Recursion Pharmaceuticals reported revenue of $74.7m for fiscal 2025, compared with $58.8m in fiscal 2024.
How much has the revenue of Recursion Pharmaceuticals grown?
Between fiscal 2020 and fiscal 2025 it went from $4.0m to $74.7m: 1,784.9% more, an average growth of 79.9% a year.
What was the best year for revenue at Recursion Pharmaceuticals?
Of its last 6 fiscal years, fiscal 2025, with $74.7m.
Where does Recursion Pharmaceuticals rank in its sector by revenue?
It ranks 308th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Recursion Pharmaceuticals come from?
From the annual report (Form 10-K) that Recursion Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Recursion Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Recursion Pharmaceuticals: the Recursion Pharmaceuticals page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.